Endothelin receptor A (ETAR) promotes tumorigenesis by stimulating cell proliferation, migration and survival. However, the mechanism of ETAR in promoting tumor growth is largely unknown. In this study, we demonstrate that ETAR stimulates colon cell proliferation, migration, and tumorigenesis through the activation of YAP/TAZ, two transcription co-activators of the Hippo tumor suppressor pathway.
Introduction
The endothelin family consists of a group of 21-amino acid peptides produced primarily in the endothelium, epithelium and smooth muscle cells (1, 2) . Among the three isoforms of endothelins, endothelin-1 (ET-1) is the most abundant and widely expressed. Extensive studies have revealed a wide range of biological functions of ET-1, including vasoconstriction, cell proliferation and cell migration (3) . In addition, ET-1 signaling has been involved in tumorigenesis in multiple tissues (4) . It acts as a growth factor in several cancers, including carcinoma of the prostate, ovary, colon, cervix, breast, kidney, lung, central nervous system (CNS) tumors as well as melanoma, Kaposi's sarcoma (KS) and bone metastasis (5, 6) .
ET-1 signals through plasma membrane-localized endothelin receptor A (ETAR)
and endothelin receptor B (ETBR), two classical G-protein coupled receptors. ETAR has been reported to be a primary vasoconstrictor and growth-promoting receptor, whereas ETBR inhibits cell growth and vascular constriction (1, 7) . Upon activation by ET-1, ETAR contributes to cell proliferation, migration, and survival. It also promotes tumor growth and progression, angiogenesis and metastatic spread (4, 5, 8) . The importance of ETAR in cancer indicates that ETAR specific antagonists (e.g. BQ123, atrasentan and ZD4054) are potential cancer therapeutic drugs. In fact, ETAR activation induces the activity of tumor-related proteinases and subsequently promotes cell migration and cell invasion which could be blocked by BQ123 (9, 10) .
Consistent with a prominent role of ET-1 in tumorigenesis, several ETAR antagonists have been tested in clinical trials. Atrasentan showed significant positive effects in brief pain inventory, prostate-specific antigen (PSA) progression and bone markers on patients in phase I and phase II trials (11) . In a phase III prostate cancer trial, atrasentan treatment showed improvement in the median time to disease progression (TTP) in patients, although the primary endpoint was not achieved (12, 13) . Atrasentan is also under phase II trials for other types of cancer, including renal, ovarian, non-small cell lung and brain cancers (11) . ZD4054 (also known as zibotentan) is a specific ETAR antagonist and has been studied in a multi-center Author Manuscript Published OnlineFirst on March 1, 2017; DOI: 10.1158/0008-5472. phase II, randomized, double blind, placebo-controlled trial. Patients that received ZD4054 experienced a 35% reduction in the risk of death, which has showed improved overall survival (14) . ZD4054 is being evaluated in hormone-resistant prostate cancer in phase III clinical trials (15, 16) . Additionally, Bosentan and YM598, two non-selective antagonists for both ETAR and ETBR, have shown promising therapeutic effect on prostate cancer in clinical trials (17).
Previous studies have shown higher expression of ETAR and ET-1 in colon cancer tissue compared to normal tissue (18) (19) (20) , while ETBR is expressed in a contrary pattern (21) . In addition, ETAR expression correlates with liver metastases of colorectal cancers (20, 21) . ETAR may also promote colon cancer cell survival in response to chemotherapy such as Cisplatin (20) . A preclinical study demonstrated that ZD4054 efficiently suppressed colorectal cancer cell growth and progression, indicating its potential role as adjuvant therapy in colorectal cancer (22) . However, the molecular mechanism of ETAR in promoting tumor cell survival, growth or metastasis in colorectal cancer is not fully understood.
The Hippo pathway was initially identified to be key player in organ size control in Drosophila and lately found to be important in human cancer (23) (24) (25) (26) . The core components of mammalian Hippo pathway contain a kinase cascade of MST1/2, MAP4Ks, and LATS1/2, in which MST1/2 or MAP4Ks phosphorylate and activate LATS. This kinase cascade regulates target genes expression by inhibiting its downstream transcriptional co-activators Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ). LATS1/2 re-strict the activity of YAP/TAZ by direct phosphorylation (27) . Phosphorylated YAP/TAZ are sequestered in the cytoplasm by 14-3-3 binding (28) (29) (30) . Inhibition of LATS1/2 activity leads to dephosphorylation of YAP/TAZ, which then translocate to the nucleus, bind to the TEA domain family transcription factors (TEAD1-4), and promote the expression of target genes (31, 32) . Generally, Hippo pathway acts as an important inhibitor of tissue growth and organ size by controlling cell proliferation, apoptosis, and migration in response to a variety of extracellular and intracellular signals, including
Materials and Methods

Chemicals
Chemicals that were used in this study: Endothelin-1, BQ123, Tetramethylrhodamine B isothiocyanate-conjugated Phalloidin, and Latrunculin B were purchased from Sigma-Aldrich (St. Louis, MO). GSK429286 and Y27632 were obtained from Selleckchem (Houston, TX). C3 was purchased from Cytoskeleton Inc (Denver, CO). Phos-tag conjugated acrylamide was purchased from Wako chemicals (Tokyo, Japan). DAPI was purchased from Invitrogen (Carlsbad, CA).
Antibodies
Antibodies for YAP (#4912), Phospho-YAP (S127) (#4911) were purchased from Cell Signaling Technology. The Lats1 (A300-477A), Lats2 (A300-479A) antibodies used in immunoprecipitation were from Bethyl Laboratories. TAZ (HPA007415) antibody was obtained from Sigma-Aldrich. Anti-TEF (610922) was purchased from BD Transduction Laboratories. Antibodies for ETAR (SC33535), Gα q/11 (SC392) and CTGF (SC14939) were from Santa Cruz Biotechnology. Anti-β-actin (A00702) was purchased from GenScript. Antibody for G S was from Abcam. All antibodies were used properly following manufacturer recommended dilutions in immunoblotting and immunofluorescence staining analysis.
Plasmids
Lats2 wild type, Lats2 K/R mutant, myc-Rho-L63 and Rho-GDI-GFP plasmids were described in (39 To generate stable YAP/TAZ knocking-down cells, pMKO-shScramble and pMKO-shTAZ retroviruses, which were produced in HEK293T cells using VSVG and GAG as packaging plasmids, were used to infect HCT116 cells. pLKO-shYAP lentivirus was produced in HEK293T cells using psPAX2 and pMD2.G as packaging plasmids .
Stable pools were selected with 1μg/mL puromycin (Amresco) for 5 days. These cells were subsequently infected with the pQCXIH-ETAR retroviruses and screened with 50μg/mL hygromycin B (Amresco) for 5 days. The cells that are resistant to both puromycin and hygromycin B were maintained and used in further experiments.
Immunoblotting
Cells were lysed in SDS sample buffer and denatured by heating on 100 o C for 10
Research. Cells were then suspended in serum-free DMEM and seeded into chambers at 50000 cells per well. The bottom chamber were filled with DMEM medium supplemented with 5% FBS. After seeding for 24 h, the membranes were fixed in 4% paraformaldehyde and stained with 0.05% crystal violet. Photos were taken by using an Olympus microscope and migrated cells were counted and quantified.
Cell proliferation
Performed in triplicate, 1×10
5 of cells were seeded into 6-well plates and cultured in McCoy's 5A medium supplemented with 5% FBS and 50 μg/ml penicillin/streptomycin. The cell culture medium was renewed every day. Cells were trypsinized and counted daily by using Countstar IC1000.
Research. 
Results
ET-1 activates YAP/TAZ in colon cancer cell lines
To explore the role of YAP/TAZ in mediating ET-1 signaling, we first tested whether ET-1 could activate YAP/TAZ in multiple cancer cell lines. ET-1 treatment in HCT116, a colon cancer cell line, led to the dephosphorylation of YAP/TAZ in a timeand dose-dependent manner (Fig. 1A & 1B) , as determined by immunoblotting with a phospho-YAP antibody (S127) and increased migration of YAP/TAZ on phos-tag gels.
Similar results were observed in SW480 and HT29 cells, two other colon cancer cell lines (Fig. 1C & Fig. S1A ). ET-1 also increased TAZ protein levels because the stability of TAZ is potently regulated by its phosphorylation. However, ET-1 did not affect YAP/TAZ phosphorylation in SW620 colon cancer cells (Fig. S1B) . Interestingly, the mRNA expression of ETAR in SW620 is much lower than that in other colon cell lines ( 
of both YAP and TAZ abolished the ET-1-induced expression of these genes (Fig. 2B &   2C ), indicating ET-1's effect on these genes was mediated by YAP/TAZ. Similarly, knocking down of the YAP/TAZ target transcription factor TEAD1/3/4 also abolished CTGF expression upon ET-1 stimulation (Fig. 2D) , further confirming the critical role of YAP/TAZ-TEAD transcription activator in the induction of ET-1 inducible genes.
ET-1 activates YAP/TAZ through ETAR and Gα q/11
ET-1 signals through ETAR to promote cell proliferation, migration, and survival.
We have found that the response of YAP/TAZ to ET-1 correlates with ETAR expression level (Fig. S1C) . To test whether ET-1 activates YAP/TAZ depends on ETAR, we used siRNA to knock down ETAR and found that ET-1 treatment could not induce YAP/TAZ dephosphorylation in the ETAR knockdown cells (Fig. 3A) . We also pretreated cell with ETAR selective antagonist BQ123 (9,10,40) and observed similar effect that ETAR inhibition prevented YAP/TAZ activation by ET-1 (Fig. 3B) . Moreover, BQ123 also blocked YAP nuclear translocation in response to ET-1 (Fig. 3C & 3D) , demonstrating that ET-1 activates YAP/TAZ through ETAR.
ET-1 activates several trimeric G proteins, including Gα q/11 and Gα s , to initiate intracellular signaling pathways (1). To determine which Gα proteins are involved in YAP/TAZ regulation, Gα q/11 or Gα s was silenced by siRNAs in HCT116 cells. Knocking down of Gα q/11 strongly blocked YAP/TAZ dephosphorylation in response to ET-1, while knockdown of Gα s had little effect on ET-1-induced YAP/TAZ dephosphorylation (Fig. 3E) . Consistently, ET-1-induced YAP nuclear accumulation in cells transfected with control or Gα s siRNA, but not Gα q/11 siRNA (Fig. 3F & 3G) . Taken (Fig. 4C) . On the other hand, expression of Rho GDP dissociation inhibitor (Rho-GDI), which binds to Rho GTPase and inhibits GTPase cycling, completely blocked ET-1-induced YAP/TAZ dephosphorylation (Fig. 4C) . Similarly, pretreatment of cells with botulinum toxin C3, a specific inhibitor of Rho GTPases, also blocked YAP/TAZ activation by ET-1 (Fig. 4D) . We also found that pretreatment with GSK429286 and Y27632, two inhibitors of Rho-associated protein kinase (ROCK), also strongly suppressed ETAR-induced YAP/TAZ dephosphorylation ( Fig. 4E ) and nuclear translocation (Fig. S3A) .
The Rho/ROCK pathway potently modulates actin cytoskeleton dynamics, particularly stress fiber formation, in response to various GPCR agonists (39) . We therefore examined whether cytoskeletal reorganization contributes to YAP/TAZ activation in response to ET-1 stimulation. Treatment with latrunculin B (Lat B), an F-actin destabilizing reagent, blocked ET-1 induced YAP/TAZ dephosphorylation ( Fig.   4F ) and nuclear accumulation (Fig. S3B) . Taken together, the above data support a model that ET-1 acts through Rho/ROCK and actin cytoskeleton to regulate the Hippo pathway, leading to YAP/TAZ activation.
ET-1 promotes cell migration, proliferation, and tumor growth through YAP/TAZ
It has been reported ETAR plays a role in the growth and progression of colorectal cancer (18, 20, 44) . YAP/TAZ are also known to promote cell proliferation (Fig. 5A & B) , suggesting an essential role of YAP/TAZ in mediating the ET-1-induced colon cancer cell migration. We then tested the role of ETAR-YAP/TAZ signaling in cell proliferation. Several stable cell lines, including ETAR overexpression, YAP/TAZ knockdown, and combination of ETAR overexpression and YAP/TAZ knockdown, were established in HCT116 cells (Fig. 5C ). Our results showed that ectopic expression of ETAR enhanced cell proliferation, while knockdown of YAP/TAZ significantly blocked the cell growth promoting effect of ETAR (Fig. 5D ). These observations indicate that YAP/TAZ play a critical role in ETAR-induced cell growth.
To gain more pathological insight of ET-1 signaling in colon tumorigenesis, we analyzed the expression level of ETAR in various cancer types in the TCGA database (Fig. S4A ). Renal clear cell carcinoma, thymoma, and esophageal carcinomas show higher expression levels of ETAR than their corresponding normal tissues. Among the tissues analyzed, colon cancer samples show a significant upregulation of ETAR expression compared to normal colon tissues (Fig. 6A) . The TCGA data is consistent with our results that most colon cancer cell lines express high levels of ETAR mRNA (Fig. S1C) . In contrast, no significance difference of ETAR expression is observed between breast cancer or liver cancer samples and their corresponding normal tissue samples, while prostate cancer samples show a decrease of ETAR expression compared to normal tissues (Fig. 6A) . Thus, the expression of ETAR appears to be 
